Healthy
Conditions
Keywords
pharmacogenetic of paracetamol, Pain threshold
Brief summary
Recent works has emphasized that the mechanism of action of paracetamol analgesic depend on its metabolism in the body, since a breakdown product of paracetamol, the AM404 is now considered the analgesic metabolite of paracetamol suggesting as paracetamol may be a pro-drug. Indeed, it has been shown that paracetamol may have a deleterious effect, especially in vulnerable populations (hepatic insufficiency, elderly). First results showed a very significant decrease in sulfatation and gluthatione and increased phase 1 metabolism of acetaminophen, which involves enzymes such as cytochrome P450. Multifactorial causes, combining nutrition (depletion of sulfur amino acids), increased detoxification of toxic metabolites of paracetamol, stress or trauma are discussed to explain the results. Clinical studies showed a great variability of pain assessment by patients and variability in the metabolic response of paracetamol. Genetic factors probably play a role remains largely unknown. The review of the literature on genetic polymorphism shows the involvement of a number of enzymes that are well known, predominantly on the metabolism of acetaminophen liver, but without connection with its analgesic effect. This is a critical missing link in the understanding of the analgesic effect of paracetamol.
Detailed description
Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week. The evaluation criterion is the difference in areas under the curve of pain thresholds to thermal and mechanical stimulations test
Interventions
Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
Sponsors
University Hospital, Clermont-Ferrand
Study design
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers * Males * Aged between 18 and 30 years
Exclusion criteria
* Subject without cons-indications of paracetamol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between Pharmacogenetic profile and pain threshold | until 14 days before the administration |
Secondary
| Measure | Time frame |
|---|---|
| Measures of thermal and mechanical pain thresholds | until 1 hour before the administration |
| Determination of blood concentration of gluthatione | until 1 hour before administration |
Countries
France
Outcome results
None listed